Matt Foehr

Person

Last mentioned: Mar 5, 2026

Stories mentioning Matt Foehr 2

OmniAb and PepGen Q4 Results Highlight Divergent Biotech Growth Strategies

OmniAb and PepGen reported full-year 2025 results, showcasing the health of the antibody discovery and neuromuscular therapeutics sectors. While OmniAb focuses on platform scalability and royalty streams, PepGen emphasizes clinical execution and cash preservation for its lead candidates.

Mar 5, 2026 2 sources

pharma Neutral

OmniAb and PepGen Reveal 2025 Financials and 2026 Clinical Roadmaps

OmniAb and PepGen have released their full-year 2025 financial results, highlighting a period of operational scaling and clinical advancement. While OmniAb continues to expand its antibody discovery ecosystem, PepGen is entering a critical phase with key data readouts expected in 2026 for its neuromuscular pipeline.

Mar 5, 2026 2 sources